Development and characterization of a mouse-panda chimeric antibody with neutralizing activity against canine distemper virus.

Abstract

Canine distemper (CD) poses as the primary virulent infectious disease threatening the safety of panda populations, and monoclonal antibodies (mAbs) represent a potential therapeutic option for the treatment of CD in pandas. To avoid immune rejection of mouse-derived mAbs in panda clinical treatment, this study utilized a mouse-derived mAb targeting the CDV-H protein to develop a mouse-panda chimeric antibody and established a CHO cell line with stable high-expression of this chimeric antibody. SDS-PAGE results indicated that the chimeric antibody expressed by CHO cells was correctly expressed. Both indirect ELISA and indirect immunofluorescence experiments demonstrated that the chimeric antibody specifically recognized the CDV-H protein and CDV virus. Furthermore, neutralization experiments confirmed its neutralizing effect on CDV. This study successfully prepared the panda-derived chimeric antibody, providing a potential candidate drug reserve for the treatment of CD in pandas.